Genentech's Tecentriq combo meets OS endpoint in first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said Tecentriq atezolizumab (MPDL3280A, RG7446) met the co-primary endpoint of improving overall survival (OS) in the Phase III IMpower150 trial as first-line treatment of advanced stage IV non-squamous non-small cell lung cancer (NSCLC). The endpoint compared Tecentriq plus Avastin bevacizumab and chemotherapy vs. Avastin and chemotherapy alone. Data from the IMpower150 trial will be presented at the American Association for Cancer Research meeting in Chicago in April.

Genentech previously reported that Tecentriq plus Avastin and chemotherapy met the co-primary endpoint of improving progression-free survival (PFS) vs. Avastin plus chemotherapy (HR=0.62, 95% CI: 0.52, 0.74, p<0.0001) (see BioCentury, Nov. 30, 2017 & Dec. 14, 2017)...